Study 2 of 153 for search of: "Cough"
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Sputum and Plasma Levels of Nociceptin and Substance P in Patients With Asthma, COPD and Chronic Cough
This study is currently recruiting participants.
Verified by National Taiwan University Hospital, June 2005
Sponsored by: National Taiwan University Hospital
Information provided by: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT00173225
  Purpose

The aims of this study are to investigate the association between sputum and plasma levels of nociceptin and substance P with cough severity and airway hyperreactivity in patients with asthma, COPD and chronic cough.


Condition
Asthma
COPD
Cough

MedlinePlus related topics: Asthma Cough
U.S. FDA Resources
Study Type: Observational
Study Design: Screening, Cross-Sectional, Defined Population, Prospective Study
Official Title: Association Between Sputum and Plasma Levels of Nociceptin and Substance P With Cough Severity and Airway Hyperreactivity in Patients With Asthma, COPD and Chronic Cough

Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 300
Study Start Date: June 2005
Estimated Study Completion Date: June 2005
Detailed Description:

Recent animal studies have found that nociceptin can inhibit cough responses induced by capsaicin. We hypothesize that sputum and plasma levels of these peptides may reflect some neurochemical alterations in airway cough reflex or neurogenic inflammation in asthma or COPD. The aims of this study are to investigate the association between sputum and plasma levels of nociceptin and substance P with cough severity and airway hyperreactivity in patients with asthma, COPD and chronic cough. We will enroll 260 patients (100 patients with asthma, 60 with COPD and 100 with chronic cough) as well as 40 healthy subjects for this study. Sputum and peripheral blood will be collected and concentrations of nociceptin and substance P will be measured by ELISA. These levels will be correlated with cough severity (symptom scores), and airway hyperresponsiveness to inhaled methacholine as measured by PC20. Sputum and plasma concentrations of both peptides will be rechecked after clinical improvements in cough or airway symptoms are achieved after therapy.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:patients with asthma, COPD, chronic cough

-

Exclusion Criteria:patients refusing blood sampling

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00173225

Contacts
Contact: Ping-Hung Kuo, MD 886-2-23123456 ext 3075 kph@ntumc.org

Locations
Taiwan
Ping-Hung Kuo Recruiting
Taipei, Taiwan, 100
Contact: Ping-Hung Kuo, MD     886-2-23123456 ext 3075     kph@ntumc.org    
Principal Investigator: Ping-Hung Kuo, MD            
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Ping-Hung Kuo, MD Department of Internal Medicine, National Taiwan University Hospital
  More Information

Study ID Numbers: 9461700531
Study First Received: September 12, 2005
Last Updated: September 12, 2005
ClinicalTrials.gov Identifier: NCT00173225  
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
nociceptin
sunstance P
asthma
COPD
cough

Study placed in the following topic categories:
Respiration Disorders
Nociceptin
Asthma
Cough
Substance P
Signs and Symptoms
Lung Diseases, Obstructive
Hypersensitivity
Respiratory Tract Diseases
Lung Diseases
Hypersensitivity, Immediate
Signs and Symptoms, Respiratory
Pulmonary Disease, Chronic Obstructive
Respiratory Hypersensitivity

Additional relevant MeSH terms:
Vasodilator Agents
Immune System Diseases
Bronchial Diseases
Therapeutic Uses
Cardiovascular Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009